TrialJournal of gastroenterology2017
Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
Toshifumi Hibi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
48 papers cite it
this paperpooled ittrialcites it